Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman

Abstract

Objectives:To evaluate the effect of Mifepristone (25 mg) on symptomatic myoma in perimenopausal women.Study Design:Open label clinical trial.Materials and Methods:Ninety three perimenopausal women of age 35-50 years having symptomatic myoma were selected from Gynecology OPD and given 25 mg Mifepristone once daily continuously for three months. Variables as; baseline uterine size, uterine volume, myoma size, volume, their number, position, characteristics, hemoglobin and blood parameters, were taken and followed monthly for six months. Bleeding and pain scores were checked on monthly visits. Changes in above parameters were tabulated during the first three months treatment phase and then next three post-treatment phase for analysis.Statistical Analysis:Was done by calculating mean, standard deviation, standard error and percentage distribution of variables.Results:Menorrhagia was the most common symptom which led patients to report to hospital. Mean uterine volume reduced to 63.69% of baseline, Mean dominant Myoma volume reduced to 53.62% and hemoglobin level raised to 137% after complete three months of treatment. Changes persisted in next three months post-treatment follow-up, while hysterectomy was required in 10 (12.2%) cases.Conclusion:Three months treatment of 25 mg Mifepristone effectively controls bleeding, reduces the uterine and myoma volume and thus can avoid blood transfusion and hysterectomy in a lot of symptomatic myoma cases.

A prospective clinical trial to evaluate the role of very low dose mifepristone 10 mg in medical management of uterine leiomyoma in tertiary care hospital from North West India

“…Kulsherestha et al and Seth et al reported statistically significant improvement in pain in lower abdomen, dysmenorrhea and back pain in their study (p<0.001). 2,7 Saharan et al, and Esteve et al, (in 5 mg group) reported 79% and 85.7% reduction in VAS score at end of 3 rd month respectively which is comparable to this study. 3,8 Treatment was well tolerated by all patients as evidenced by adherence of the patient to treatment.…”

Role of Mifepristone in treatment of uterine fibroid: an experience from tertiary care centre in South India

“…Comparable results of Shikha Seth et al reported that Hb% raised by 2.8gm% at the end of treatment. 12 In present study percentage of fibroid volume reduction noted was 38.7%, similarly in study conducted by Kulshrestha et al there was 36% reduction with 25mg of Mifepristone. Hysterectomy was done in 7% of patients, in whom heavy menstrual bleeding continued despite of Mifepristone treatment.…”

Study the effect of mifepristone on fibroid and uterine volume

“…10 Seth et al also did a study with 25mg mifepristone daily for 3 months and resulted in a significant reduction in the volume of fibroid by 53.6 per cent. 11 In present study, we saw a reduction in the size of the uterine cavity from baseline to 3 months. The mean volume of the uterus at baseline was 105.4cc, which further reduced significantly to 43.9cc at the end of 3 months of treatment.…”